Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company based in New York, focusing on developing innovative therapies for mental health conditions using a unique AI-powered platform.
Founders
Gilgamesh Pharmaceuticals was part of the Y-Combinator batch S20. The combination of their clinical-stage focus on mental health science and a strong foundation in medicinal chemistry, intellectual property strategy, and drug development demonstrates the deep expertise the founding team brought together.
Services
Gilgamesh Pharmaceuticals focuses on drug discovery and delivery within the healthcare sector. Their primary service is developing innovative new chemical entities (NCEs) to treat various mental health conditions. Utilizing a blend of medicinal chemistry, neuroscience, and an AI-powered translational platform, they offer targeted solutions for conditions like depression and opioid use disorder.
Products
Gilgamesh Pharmaceuticals develops a range of products designed to address mental health disorders. Their portfolio includes NMDAR Antagonists, 5-HT2AR Agonists, and Safer Ibogaine Analogs, targeting conditions such as depression and opioid use disorder. These products are part of their mission to create rapid-acting, durable therapies that shift the focus from symptom management to addressing fundamental disease drivers.
Collaborations
Gilgamesh Pharmaceuticals collaborates with prominent research institutions like Columbia University, NIDA, NYU, and Yale. These partnerships enable them to stay at the forefront of biotechnological innovation, enhancing their ability to develop cutting-edge treatments for mental health conditions.
Funding
Gilgamesh Pharmaceuticals has attracted funding from notable investors such as Y Combinator and Prime Movers Lab. They successfully raised $39 million in a Series B funding round, which will be used to advance their mental health treatment initiatives and accelerate the development of their innovative drug portfolio.
